Globus Medical logged a -2.3% change during today's afternoon session, and is now trading at a price of $59.17 per share. The S&P 500 index moved 1.0%. GMED's trading volume is 1,769,375 compared to the stock's average volume of 1,482,759.
Globus Medical trades -30.52% away from its average analyst target price of $85.17 per share. The 12 analysts following the stock have set target prices ranging from $68.0 to $105.0, and on average have given Globus Medical a rating of buy.
If you are considering an investment in GMED, you'll want to know the following:
-
Globus Medical's current price is 161.7% above its Graham number of $22.61, which implies that at its current valuation it does not offer a margin of safety
-
Globus Medical has moved -11.9% over the last year, and the S&P 500 logged a change of 11.9%
-
Based on its trailing earnings per share of 1.34, Globus Medical has a trailing 12 month Price to Earnings (P/E) ratio of 44.2 while the S&P 500 average is 29.3
-
GMED has a forward P/E ratio of 17.3 based on its forward 12 month price to earnings (EPS) of $3.42 per share
-
Its Price to Book (P/B) ratio is 1.96 compared to its sector average of 3.19
-
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
-
Based in Audubon, the company has 5,300 full time employees and a market cap of $8.01 Billion.
